OSE Immunotherapeutics S.A.
OSE.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 59.2% | -99% | 9,402.1% | – |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 0% | 103.7% | 83.6% | 100% |
| EBITDA | -€0 | -€0 | €0 | -€0 |
| % Margin | -1,122.3% | -2,339.6% | 73.4% | -1,346.5% |
| Net Income | -€0 | -€0 | €0 | -€0 |
| % Margin | -1,141.7% | -2,374.2% | 69.2% | -1,282.3% |
| EPS Diluted | -0.68 | -0.91 | 2.63 | -0.54 |
| % Growth | 25.3% | -134.6% | 587% | – |
| Operating Cash Flow | -€0 | -€0 | €0 | -€0 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | €0 | -€0 |